High-Risk Neuroblastoma Treatment Review

Smith, Valeria; Foster, Jennifer

doi:10.3390/children5090114

Cited by 169 publications

(167 citation statements)

References 38 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…A limited number of studies has monitored immune profiles during chemotherapy in cancer patients. Monitoring lymphocyte levels during and after chemotherapy in hematopoietic and solid tumors generally showed increased EFS in patients with higher lymphocyte counts at diagnosis as well as after induction chemotherapy [42,[47][48][49] In addition, fast monocyte recovery after chemotherapy is predictive for EFS in patients with leukemias and lymphomas [50,51]. In line with these data, an elevated neutrophil to lymphocyte ratio after chemotherapy, but before surgical resection of the NBL tumor, was associated with decreased OS [52].…”

Section: Chemotherapymentioning

confidence: 70%

“…In general, high-risk NBL patients receive 5-8 cycles of intensive chemotherapy including platinum, alkylating, and topoisomerase agents. In North-America, induction regimens include vincristine, doxorubicin, cyclophosphamide, cisplatin, and etoposide, while the Society of pediatric oncology Europe NBL group (SIOPEN) used a rapid COJEC regimen that gives eight cycles with combinations of vincristine, carboplatin, etoposide, cyclophosphamide, and cisplatin [47].…”

Section: Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Monitoring Immune Responses in Neuroblastoma Patients during Therapy

Szanto

Cornel

Vijver

et al. 2020

Cancers

View full text Add to dashboard Cite

Neuroblastoma (NBL) is the most common extracranial solid tumor in childhood. Despite intense treatment, children with this high-risk disease have a poor prognosis. Immunotherapy showed a significant improvement in event-free survival in high-risk NBL patients receiving chimeric anti-GD2 in combination with cytokines and isotretinoin after myeloablative consolidation therapy. However, response to immunotherapy varies widely, and often therapy is stopped due to severe toxicities. Objective markers that help to predict which patients will respond or develop toxicity to a certain treatment are lacking. Immunotherapy guided via immune monitoring protocols will help to identify responders as early as possible, to decipher the immune response at play, and to adjust or develop new treatment strategies. In this review, we summarize recent studies investigating frequency and phenotype of immune cells in NBL patients prior and during current treatment protocols and highlight how these findings are related to clinical outcome. In addition, we discuss potential targets to improve immunogenicity and strategies that may help to improve therapy efficacy. We conclude that immune monitoring during therapy of NBL patients is essential to identify predictive biomarkers to guide patients towards effective treatment, with limited toxicities and optimal quality of life.

show abstract

Section: Chemotherapymentioning

confidence: 70%

Section: Chemotherapymentioning

confidence: 99%

Monitoring Immune Responses in Neuroblastoma Patients during Therapy

Szanto

Cornel

Vijver

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…(37) Moreover, intensive international collaboration research efforts are still ongoing as cure rates for the high-risk NB have shown only modest improvement. (38) We found that 30% of 36.908 authors contributing to NB research were "core" authors, publishing two or more NB related articles. Correspondingly, the estimation of Lotka´s law indicates similarity in author´s productivity according to theoretically expectation.…”

Section: Discussionmentioning

confidence: 85%

A Scientometric Analysis of Neuroblastoma Research

Martynov

Klima-Frysch

Schoenberger

2020

Preprint

View full text Add to dashboard Cite

Background: There are thousands of research articles in the field of neuroblastoma that have been published over the past few decades. However, the heterogeneity and variable quality of scholarly data may challenge scientists or clinicians to survey all published articles. However, holistic measuring and analyzing of neuroblastoma related literature by sophisticated mathematical methods can provide a unique opportunity to gain deep insights into the global research performance and collaborative architectonical structure within the neuroblastoma scientific community. In this scientometric study, we aim to determine the extent of the scientific output related to neuroblastoma research, focusing on the time period between 1980 and 2018. Methods: We apply novel scientometric tools, including Bibliometrix R package, biblioshiny, VOSviewer, and CiteSpace IV for comprehensive science mapping analysis of extensive bibliographic metadata which was retrieved from the Web of ScienceTM Core Collection database. Results: We demonstrate the enormous proliferation of neuroblastoma research during last the 38 years, including 12,435 documents published in 1,828 academic journals by 36,908 authors from 86 different countries. We determine the proportion of highly cited and never cited papers, “occasional” and “core” authors and journals. We identify the six most important clusters of authors and their interactions. Further, we show 10 (11.6%) of 86 countries were responsible for the three quarters of NB-related research output. Conclusions: These findings are crucial for researchers, clinicians, journal editors, and consortiums working in neuroblastoma area to understand the strengths and potential gaps in neuroblastoma research and to plan future investments in data collection and science policy. This first scientometric study of global neuroblastoma research performance provides valuable insight into the scientific landscape, co-authorship network architecture, international collaboration, and interaction within the neuroblastoma community.

show abstract

“…Generally older children with metastatic tumors with extra MYCN copies are accepted as high stage tumors; and infants with even metastatic tumors without MYCN copies are considered as low risk. Chemotherapy of neuroblastoma generally includes combination of chemotherapeutic agents such as cyclophosphamide, cisplatin, carboplatin, vincristine, doxorubicin (Adriamycin), etoposide, topotecan, and busulfan (7,8) . While all of these treatment strategies have their own adverse effects, the adverse effects related to systemic chemotherapy is much restrictive due to their higher mortality rates.…”

Section: Introductionmentioning

confidence: 99%

Antiproliferative Effects of Carvacrol on Neuroblastoma Cells

Koçal¹,

Pakdemirli²

2020

BUCH

View full text Add to dashboard Cite

Objective: Neuroblastoma is a pediatric solid tumor that originates from the neural crest. The survival rate of these malignancies is below 50 %. The most common treatments for the disease have several adverse effects which make them invasive for patients and limits the applicability as well as continuity of the treatment. Therefore, researchers seek new agents to reduce adverse effects in order to improve the treatment. In this wise, plant-derived phytochemicals are promising drug candidates, such as carvacrol which has anti-cancer features in some cancers. Method: Human neuroblastoma cell lines, KELLY (N-MYC positive) and SH-SY5Y (N-MYC negative) were grown in RPMI 1640 (KELLY) or DMEM (SH-SY5Y). Cells were treated with a range of concentration of carvacrol. Cellular proliferation was monitored by using xCELLigence Real-Time Cell Analyzer (RTCA) (ACEA Biosciences, Inc.) device to evaluate the antiproliferative effect of carvacrol on the neuroblastoma cells. Results: Considering the proliferation curve of SH-SY5Y, results indicate that carvacrol has antiproliferative effects on N-MYC negative neuroblastoma cells, SH-SY5Y cells at all concentrations. Conclusion: The data illuminate that the carvacrol has an antiproliferative role on neuroblastoma cells. In this context, this phyto-compound might be a promising agent for the treatment of this malignancy.

show abstract

High-Risk Neuroblastoma Treatment Review

Cited by 169 publications

References 38 publications

Monitoring Immune Responses in Neuroblastoma Patients during Therapy

Monitoring Immune Responses in Neuroblastoma Patients during Therapy

A Scientometric Analysis of Neuroblastoma Research

Antiproliferative Effects of Carvacrol on Neuroblastoma Cells

Contact Info

Product

Resources

About